MSD’s Keytruda-Padcev combo secures EC approval for MIBC
The EC has approved MSD's Keytruda in combination with Padcev as a neoadjuvant treatment for muscle-invasive bladder cancer (MIBC).
Read the full article on the original site.
Read Full Article